Loading…
Reported covered position: Deputy Health Policy Director, Committee on Senate Health, Education, Labor and Pensions; Health Policy Assistant, Sen. Richard Burr; Intern, Rep. Robert Portman
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
IRA WATCHDOG via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Source: Senate LDA
| WAKE FOREST UNIVERSITY |
| 8 |
| 2025–2026 |
| IRA WATCHDOG | 7 | 2025–2026 |
| ResMed Corp. | 6 | 2024–2025 |
| SCHWEIGER DERMATOLOGY GROUP | 6 | 2024–2025 |
| DUKE UNIVERSITY HEALTH SYSTEM | 5 | 2025 |
| PONYA DIAGNOSTICS, LLC | 5 | 2025–2026 |
| WE WORK FOR HEALTH | 5 | 2024–2025 |
| BIOGEN, INC. | 4 | 2025–2026 |
| CORVENT MEDICAL, INC. | 4 | 2026 |
| AIDOC, INC. | 3 | 2025–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 3 | 2026 |
| GALDERMA LABORATORIES, L.P. | 3 | 2026 |
| NOVARTIS | 3 | 2025–2026 |
| ADVOCATE HEALTH | 2 | 2024 |
| RAINFALL HEALTH | 2 | 2026 |
| ASSOCIATION OF AMERICAN UNIVERSITIES | 1 | 2025 |
| SCOUT | 1 | 2026 |
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: NOVARTIS · Firm: DLA PIPER LLP (US)
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Policies and proposals impacting higher education for health sciences. Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
National Defense Authorization Act for Fiscal Year 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
National Defense Authorization Act for Fiscal Year 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Protect College Sports Act of 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Protect College Sports Act of 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax. Federal Student Aid.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 1, One Big Beautiful Bill Act, federal student aid.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, university endowment tax.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 1, One Big Beautiful Bill Act, federal student aid.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: WAKE FOREST UNIVERSITY · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, university endowment tax.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act of FY2026, provisions regarding the DETERRENT Act.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: SCHWEIGER DERMATOLOGY GROUP · Firm: DLA PIPER LLP (US)
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025.
National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
National Defense Authorization Act for Fiscal Year 2026
Client: DUKE UNIVERSITY · Firm: DLA PIPER LLP (US)
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act of FY2026, provisions regarding the DETERRENT Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
EPIC Act of 2025
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. 832, EPIC Act of 2025.
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Firm: DLA PIPER LLP (US)
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
VALID Act of 2023
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for public research universities. H.R. 9029, Labor-HHS-Education Appropriations, FY2025, provisions regarding Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for public research universities. H.R. 9029/S. 4942, Labor-HHS-Education Appropriations, FY2025, provisions regarding Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for public research universities. H.R. 9029/S. 4942, Labor-HHS-Education Appropriations, FY2025, provisions regarding Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
National Defense Authorization Act for Fiscal Year 2025
Client: ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) · Firm: DLA PIPER LLP (US)
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for public research universities. H.R. 9029/S. 4942, Labor-HHS-Education Appropriations, FY2025, provisions regarding Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL · Firm: DLA PIPER LLP (US)
Policies and proposals impacting higher education for public research universities. H.R. 9029/S. 4942, Labor-HHS-Education Appropriations, FY2025, provisions regarding Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
Medicare policies.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
GALDERMA LABORATORIES, L.P. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Trade-related public policy around tariffs and intellectual property.
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · fourth_quarter · RR
Harley Jacobsen Clinical Trial Participant Income Exemption Act; Medicaid eligibility policies as it relates to compensation for participation in clinical trials, clinical trial participation policies related to the Anti-Kickback Statute.
Harley Jacobsen Clinical Trial Participant Income Exemption Act; Medicaid eligibility policies as it relates to compensation for participation in clinical trials, clinical trial participation policies related to the Anti-Kickback Statute.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid. Department of Agriculture/FDA Appropriations, FY2027, provisions related to Centers of Excellence funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
RAINFALL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · Q3
CMS TEAM model, value-based care arrangements. CMS CJR-X model.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · second_quarter · 2A
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Issues related to CMS reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GALDERMA LABORATORIES, L.P. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES
RAINFALL HEALTH via DLA PIPER LLP (US)
2026 · third_quarter · RR
CMS TEAM model, value-based care arrangements.
GALDERMA LABORATORIES, L.P. via DLA PIPER LLP (US)
2026 · second_quarter · RR
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement. Trade policies and agreements, including IP protections, and administrative tariff actions.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Medicare policies.
National security issues related to pharmaceutical industry, including supply chain.
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
NOVARTIS via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Tariffs and biotechnology issues related to Treasury and competition with China.
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to rare disease and treatment. Drug pricing policy. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Trade-related public policy around tariffs and intellectual property.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements. Issues related to the 340B program.
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to federal research funding. Federal student aid. S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals impacting higher education for health sciences. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act). S. 4668, Protect College Sports Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
IRA WATCHDOG via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies and proposals related to university endowment tax.
Policies and proposals related to federal research funding. H.R. 8800, National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid. S. 4668, Protect College Sports Act of 2026. H.R. 9260, Departments of Labor-HHS-Education Appropriations, FY2027, provisions related to conditions for research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to CMS reimbursement. FDA issues.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IRA WATCHDOG via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Trade policies and agreements, including IP protections, and administrative tariff actions.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
BIOGEN, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Government systems for AI integration. Regulation of AI medical technology.
Government systems for AI integration. Medicare coverage for AI technology.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to federal research funding. National Defense Authorization Act for FY2027, provisions related to conditions for research funding. Federal student aid.
Policies and proposals related to university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals impacting higher education for health sciences. Departments of Labor-HHS-Education Appropriations, FY2027, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies and proposals related to federal research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIVIOR INC. via DLA PIPER LLP (US)
2026 · first_quarter · 1T
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
Filing targets: SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · first_quarter · RR
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Government systems for AI integration.
Government systems for AI integration.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
AIDOC, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Government systems for AI integration.
Government systems for AI integration.
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIVIOR INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 2586, Reentry Act of 2025, policies related to reimbursement of substance use disorder treatment.
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act for FY2026, provisions related to conditions for research funding.
Policies and proposals related to university endowment tax. Federal Student Aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid. H.R. 4312, Student Compensation and Opportunity through Rights and Endorsements Act (SCORE Act).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOGEN, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to rare diseases including Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Lou Gehrig's Disease. Drug pricing and drug development policies. Screening and diagnosis. Patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues. Orphan Drug Act. Issues related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials. Policies related to value based arrangements.
Issues related to rare disease and treatment. Drug pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Alzheimer's disease. Issues related to Medicare Part B and D.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAZARUS AI via DLA PIPER LLP (US)
2025 · fourth_quarter · 4T
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Policies and proposals related to federal research funding. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to CMS reimbursement.
Issues related to CMS reimbursement.
Issues related to CMS reimbursement. FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PONYA DIAGNOSTICS, LLC via DLA PIPER LLP (US)
2025 · fourth_quarter · RR
Issues related to skin substitutes. Issues related to the rural health fund. Skin Substitutes Access and Payment Reform Act of 2025. Clinical lab issues. The Rural Health Transformation Program.
Issues related to skin substitutes. Issues related to the rural health fund. Skin Substitutes Access and Payment Reform Act of 2025. Clinical lab issues. The Rural Health Transformation Program.
Issues related to skin substitutes. Issues related to the rural health fund. Skin Substitutes Access and Payment Reform Act of 2025. Clinical lab issues. The Rural Health Transformation Program.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · third_quarter · Q3
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals impacting higher education for health sciences. H.R. 5304/S. 2587, Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming. Federal student aid.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LAZARUS AI via DLA PIPER LLP (US)
2025 · third_quarter · Q3
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals related to federal research funding. H.R. 3838/S. 2296, National Defense Authorization Act of FY2026, provisions regarding the DETERRENT Act.
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax. Federal Student Aid.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals related to federal research funding. H.R. 1, One Big Beautiful Bill Act, federal student aid.
H.R. 1, One Big Beautiful Bill Act, university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · third_quarter · Q3
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
INDIVIOR INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Medicaid Reentry Act, policies related to reimbursement of substance use disorder treatment.
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.
Filing targets: SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via DLA PIPER LLP (US)
2025 · third_quarter · 3T
Issues related to medical devices and healthcare policy. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Impact of Medicare Drug Price Negotiation Program on patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRA WATCHDOG via DLA PIPER LLP (US)
2025 · second_quarter · RR
Impact of Medicare Drug Price Negotiation Program on patients.
LAZARUS AI via DLA PIPER LLP (US)
2025 · second_quarter · 2A
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Policies and proposals related to federal research funding.
Policies and proposals related to university endowment tax. H.R. 1, One Big Beautiful Bill Act, university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Policies and proposals impacting higher education for health sciences. Departments of Labor-HHS-Education Appropriations, FY2026, provisions regarding health workforce programming.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Policies and proposals related to federal research funding. H.R. 1, One Big Beautiful Bill Act, federal student aid.
H.R. 1, One Big Beautiful Bill Act, university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · second_quarter · Q2
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025. Medicare physician fee schedule issues.
RESMED CORP. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues related to medical devices and healthcare policy. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIVIOR INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Medicaid Reentry Act, policies related to reimbursement of substance use disorder treatment.
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.
Filing targets: SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAZARUS AI via DLA PIPER LLP (US)
2025 · second_quarter · Q2
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via DLA PIPER LLP (US)
2025 · second_quarter · RR
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
ASSOCIATION OF AMERICAN UNIVERSITIES via DLA PIPER LLP (US)
2025 · second_quarter · RR
Research security, research funding, and the importance of American research enterprise and higher education.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Issues related to medical devices and healthcare policy. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via DLA PIPER LLP (US)
2025 · first_quarter · 1T
Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.
Filing targets: SENATE
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies and proposals related to federal research funding.
Policies and proposals related to university endowment tax.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
INDIVIOR INC. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Medicaid Reentry Act, policies related to reimbursement of substance use disorder treatment.
General education on issues related to the Drug Enforcement Agency (DEA). Issues related to substance use addiction and treatment, including NIH/HHS funding levels.Issues related to access to addiction treatments, including telehealth.
Filing targets: SENATE
LAZARUS AI via DLA PIPER LLP (US)
2025 · first_quarter · Q1
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies and proposals related to coverage and reimbursement, federal government research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCHWEIGER DERMATOLOGY GROUP via DLA PIPER LLP (US)
2025 · first_quarter · Q1
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies and proposals related to university endowment tax.
Policies and proposals related to federal research funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies and proposals impacting higher education for health sciences. Labor-HHS-Education Appropriations, FY2025 and FY2026, provisions regarding health workforce programming.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DUKE UNIVERSITY HEALTH SYSTEM via DLA PIPER LLP (US)
2025 · first_quarter · RR
Policies and proposals related to coverage and reimbursement, federal government research funding.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via DLA PIPER LLP (US)
2025 · first_quarter · RR
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
DUKE UNIVERSITY via DLA PIPER LLP (US)
2025 · first_quarter · RR
Policies and proposals related to federal research funding and university endowment tax.
Policies and proposals related to federal research funding and university endowment tax.
WAKE FOREST UNIVERSITY via DLA PIPER LLP (US)
2025 · first_quarter · RR
Policies and proposals related to federal research funding and university endowment tax.
Policies and proposals related to federal research funding and university endowment tax.
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Legislative and regulatory proposals and policies regarding medical device innovation. H.R. 2369, Verifying Accurate, Leading-edge IVCT Development (VALID) Act of 2023. H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. S. 4638, National Defense Authorization Act for FY2025, provisions regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAZARUS AI via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
AI policies and programs within the Department of Defense, the Intelligence Community, and healthcare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Pharmacy benefit manager reform, intellectual property issues, and other drug pricing related issues.
Filing targets: SENATE
Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Trade policies and agreements, including IP protections, and administrative tariff actions.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Healthcare provisions in appropriations and budget legislation.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
National security issues related to pharmaceutical industry, including supply chain.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.
S. 832, EPIC Act of 2025.
Medicare policies.
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S. Con. Res. 7, Budget Resolution for FY2025, provisions impacting pharmaceuticals. H. Con. Res. 14, Budget Resolution for FY2025, provisions impacting pharmaceuticals.
National security issues related to pharmaceutical industry, including supply chain.
Trade policies and agreements, including IP protections, and administrative tariff actions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.